Real-world survival outcomes of wedge resection versus lobectomy for cT1a/b cN0 cM0 non-small cell lung cancer: a single center retrospective analysis.

lobectomies lung cancer multivariable analysis outcomes survival analysis wedge resections

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 21 05 2023
accepted: 19 07 2023
medline: 4 9 2023
pubmed: 4 9 2023
entrez: 4 9 2023
Statut: epublish

Résumé

JCOG0802/WJOG4607L showed benefits in overall survival (OS) of segmentectomy. CALGB 140503 confirmed that sublobar resection was not inferior to lobectomy concerning recurrence-free survival (RFS) but did not provide specific OS and RFS according to the techniques of sublobar resections. Hence, we retrospectively analyze the survival differences between wedge resection and lobectomies for stage IA lung cancer. We reviewed the clinical records of patients with clinical stage IA NSCLC over 20 years. The inclusion criteria were: preoperative staging with CT scan and whole body CT/PET; tumor size <20 mm; wedge resections or lobectomies with or without lymph node dissection; NSCLC as the only primary tumor during the follow-up period. We excluded: multiple invasive lung cancer; positive resection margin; preoperative evidence of nodal disease; distant metastasis at presentation; follow-up time <5 years. The reverse Kaplan - Meier method estimated the median OS and PFS and compared them by the log-rank test. The stratified backward stepwise Cox regression model was employed for multivariable survival analyses. 539 patients were identified: 476 (88.3%) lobectomies and 63 (11.7%) wedge resections. The median OS time for the whole cohort was 189.7 months (range: 173.7 - 213.9 months). The 5-year wedge resection and lobectomy OS were 82.2% and 87.0%. The 5-year RFS of wedge resection and lobectomy were 17.8% and 28.9%. The log-rank test showed no significant differences (p = 0.39) between wedge resections and lobectomies regarding OS and RFS (p = 0.23). Lobectomy and wedge resection are equivalent oncologic treatments for individuals with cN0/cM0 stage IA NSCLC <20 mm. Validating the current findings requires a prospective, randomized comparison between wedge resection and standard lobectomy to establish the prognostic significance of wedge resection.

Sections du résumé

Background UNASSIGNED
JCOG0802/WJOG4607L showed benefits in overall survival (OS) of segmentectomy. CALGB 140503 confirmed that sublobar resection was not inferior to lobectomy concerning recurrence-free survival (RFS) but did not provide specific OS and RFS according to the techniques of sublobar resections. Hence, we retrospectively analyze the survival differences between wedge resection and lobectomies for stage IA lung cancer.
Methods UNASSIGNED
We reviewed the clinical records of patients with clinical stage IA NSCLC over 20 years. The inclusion criteria were: preoperative staging with CT scan and whole body CT/PET; tumor size <20 mm; wedge resections or lobectomies with or without lymph node dissection; NSCLC as the only primary tumor during the follow-up period. We excluded: multiple invasive lung cancer; positive resection margin; preoperative evidence of nodal disease; distant metastasis at presentation; follow-up time <5 years. The reverse Kaplan - Meier method estimated the median OS and PFS and compared them by the log-rank test. The stratified backward stepwise Cox regression model was employed for multivariable survival analyses.
Results UNASSIGNED
539 patients were identified: 476 (88.3%) lobectomies and 63 (11.7%) wedge resections. The median OS time for the whole cohort was 189.7 months (range: 173.7 - 213.9 months). The 5-year wedge resection and lobectomy OS were 82.2% and 87.0%. The 5-year RFS of wedge resection and lobectomy were 17.8% and 28.9%. The log-rank test showed no significant differences (p = 0.39) between wedge resections and lobectomies regarding OS and RFS (p = 0.23).
Conclusions UNASSIGNED
Lobectomy and wedge resection are equivalent oncologic treatments for individuals with cN0/cM0 stage IA NSCLC <20 mm. Validating the current findings requires a prospective, randomized comparison between wedge resection and standard lobectomy to establish the prognostic significance of wedge resection.

Identifiants

pubmed: 37664070
doi: 10.3389/fonc.2023.1226429
pmc: PMC10470827
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1226429

Informations de copyright

Copyright © 2023 Bertolaccini, Cara, Chiari, Diotti, Glick, Mohamed, Uslenghi, Mazzella, Brambilla, Bertolotti, Sedda and Spaggiari.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Semin Thorac Cardiovasc Surg. 2020 Autumn;32(3):582-590
pubmed: 31401180
Ann Thorac Surg. 2018 May;105(5):1483-1491
pubmed: 29462591
Front Oncol. 2019 Jul 03;9:593
pubmed: 31334118
Int J Surg. 2019 Dec;72:156-165
pubmed: 31704426
Ann Surg Oncol. 2022 Mar;29(3):1868-1879
pubmed: 34613537
Ann Surg Oncol. 2021 Nov;28(12):7219-7227
pubmed: 33900499
J Clin Oncol. 2017 Apr 10;35(11):1162-1170
pubmed: 28029318
N Engl J Med. 2023 Feb 9;388(6):489-498
pubmed: 36780674
Cancer Med. 2022 Dec;11(24):4784-4795
pubmed: 35570370
Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3
pubmed: 7677489
Lancet. 2022 Apr 23;399(10335):1607-1617
pubmed: 35461558
Cancers (Basel). 2023 Mar 27;15(7):
pubmed: 37046654
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738

Auteurs

Luca Bertolaccini (L)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Andrea Cara (A)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Matteo Chiari (M)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Cristina Diotti (C)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Nimrod Glick (N)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Shehab Mohamed (S)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Clarissa Uslenghi (C)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Antonio Mazzella (A)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Daniela Brambilla (D)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Raffaella Bertolotti (R)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Giulia Sedda (G)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Lorenzo Spaggiari (L)

Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Classifications MeSH